Samsung Biologics announced on November 26, 2025, that it has gone on to achieve a whopping 400 regulatory manufacturing approvals all over the world due to its quality competitiveness.
It is worth noting that as of November 2025, Samsung Biologics has secured 400 manufacturing approvals that have come from many regulatory agencies across the world. These approvals include 49 from the U.S. Food and Drug Administration – FDA and 46 from the European Medicines Agency – EMA. This achievement comes only a year after attaining 300 approvals in October 2025, which means that the company has gone on to add another 100 approvals in a very short span. This kind of fast accumulation of manufacturing approval track records goes on to reflect the expansion of production capacity as well as the increase in manufactured products of the company. Apparently, Samsung also maintains the highest rate when it comes to passing regulatory inspections in the industry.
The fact is that regulatory manufacturing approval is indeed a part of the drug authorization process and also indicates that the overall process of manufacturing and quality control for a particular pharmaceutical product complies with the Good Manufacturing Practice GMP standards of every country. It is a procedure that can be termed as mandatory for CDMO – Contract Development and Manufacturing Organization companies to go ahead and supply pharmaceuticals to their respective markets. Due to the fact that dozens of experts and many months of verification are needed for every product, it is considered to be a major indicator for assessing the quality as well as operational capabilities that a CDMO company possesses.
Understandably, the reasons why Samsung Biologics has been able to consistently accumulate manufacturing approvals, even from the strict global regulatory agencies within the United States and Europe, It is because of the development of specialized personnel, a quality management system that’s digital-based, and also standardization related to regulatory response processes.
Ever since its establishment in 2011, Samsung Biologics has gone ahead and operated a dedicated inspection team and also invested in systematic personnel growth. Through continuously strengthening the evaluation of the upgraded regulatory guidelines, preparation for client inspections, and inspection response training, Samsung has expanded the number of personnel that are capable of handling manufacturing approvals from around 70 that were there in 2015 to almost 500 today.
Moreover, the company has also established a digital-based GMP – Good Manufacturing Practice data management system so as to integrate as well as manage production and quality data by way of electronic documentation and also electronic quality systems. Through digitizing the massive amounts of data that are generated at the time of biopharmaceutical production in sync with the GMP regulations and simultaneously tracking as well as storing it in real time, the company can go ahead and respond immediately and precisely to data verification requirements from regulatory agencies as well as clients.
And finally, based upon the extensive experience with global regulatory inspections, Samsung has gone on to standardize the overall process, right from inspection preparation as well as on-site response to the post-inspection corrective and preventive steps. All this goes on to help Samsung Biologics to maintain balanced and continuous quality benchmarks and response systems, even when the product or process characteristics are different, and hence continuously making trust with regulatory agencies more effective and robust.
The CEO of Samsung Biologics, John Rim, opines that attaining 400 regulatory manufacturing approvals throughout the world again goes on to prove their quality competitiveness that’s digital-based as well as standardized operational capacities, adding that they will continue to strengthen their quality management, technological innovation, and also regulatory response capacities in order to become the most trusted partner for pharmaceutical companies across the globe.
